Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GD-N1801 is a biological extract derived from the American cockroach (*Periplaneta americana*), developed by Sichuan Good Doctor Panxi Pharmaceutical for the treatment of chronic wounds, including diabetic foot ulcers. The extract is rich in bioactive peptides, amino acids, and nucleosides that facilitate the wound-healing process. Its mechanism of action involves the stimulation of fibroblast proliferation, the enhancement of granulation tissue formation, and the regulation of inflammatory mediators. GD-N1801 is designed to accelerate the transition from the inflammatory phase to the proliferative phase of wound healing, making it a potential therapy for hard-to-heal ulcers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on GD-N1801.